On 18 August the FDA approved a supplement to NDA 211962, Hikma's vancomycin hydrochloride product marketed as TYZAVAN. A supplemental approval is a change to an already licensed application - it can cover manufacturing, presentation, labelling or an added population - and the approval record names the application and the sponsor without stating which of those it was.
So the accurate reading is narrow: an existing intravenous vancomycin product has had a supplement cleared, not a new antibiotic approved and not a new indication established. Anyone whose prescribing would change should read the current US prescribing information rather than infer the change from the approval listing.
What is worth noting is the product category. Ready-to-use and premixed vancomycin presentations exist precisely to remove a preparation step that has been a recurring source of dosing error, and India's vancomycin supply is overwhelmingly reconstituted vials. Whether this particular supplement touches presentation is not something the record supports saying.
- Read this as a supplemental approval to an existing application, not a new approval.
- Check the current prescribing information before assuming anything about the product has changed for your patients.
- The approval is FDA only - it says nothing about CDSCO status or availability in India.
- Keep vancomycin decisions anchored to local susceptibility data and therapeutic drug monitoring, which no label change alters.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free